Seegene appoints Dr. Glen Hansen as Head of Medical Affairs of U.S. subsidiary
SEOUL, South Korea, March 17, 2022 /PRNewswire/ -- Seegene Inc.
Seegene appoints Richard Creager as CEO of U.S. subsidiary to bolster U.S. business
SEOUL, South Korea, March 2, 2022 /PRNewswire/ -- Seegene Inc.
Seegene unveils new assay optimized for on-site testing in 'living with Covid-19' era
SEOUL, South Korea, Feb. 24, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today, announced the CE-IVD marking of its Allplex™ SARS-CoV-2 fast MDx Assay. This new assay is optimized for the 'living with COVID-19' era, where mass, swift and ...
Seegene Announces Q4 and Full-Year 2021 Financial Results
* Total sales of 2021 stood at KRW 1.37 trillion, a 22% increase YoY * Q4 Revenue of KRW 410 billion, up 34% QoQ * Operating profit held steady YoY at KRW 666.7 billion despite its tripled strategic investments in R&D * Seegene to make a strategic shift to a 'molecular diagnostics(MDx) plat...
Seegene Signs Supply Deal to Deliver 4 million COVID-19 Tests to Brazil
SEOUL, South Korea, Feb. 10, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostic company, today announced that it has signed a supply deal with the Ministry of Health ofBrazil to deliver four million COVID-19 tests. Since January 2022, Brazil has battled a...
Seegene to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing
SEOUL, South Korea, Jan. 19, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced today the upcoming launch of the Allplex™ SARS-CoV-2 Fast PCR Assay, which can deliver PCR results in just 60 minutes. The company says that this assay is exp...
Seegene Continues to Support Israel's Effort to Manage the Omicron Variant With Timely Delivery of Five Million Tests
SEOUL, South Korea, Jan. 17, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced today that it has delivered over five million COVID-19 tests toIsrael to help detect and mitigate the spread of the Omicron variant. The company sent 1.7 mill...
Seegene's Allplex™ SARS CoV-2 FluA/FluB/RSV Assay approved under Health Canada's Interim Order
SEOUL, South Korea, Jan. 17, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostic company, announced it has received approval of its Allplex™ SARS CoV-2 FluA/FluB/RSV Assay under Health Canada's Interim Order onJanuary 11. Seegene's Allplex™ SARS CoV-2 Flu...
Seegene Unveils Blueprint for the Future of Molecular Diagnostics, Including Open Development Platform at the 40th Annual J.P. Morgan Healthcare Conference
SEOUL, South Korea, Jan. 13, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics (MDx) company, today, unveiled its blueprint for the future during a presentation at the 40th annual J.P. Morgan Healthcare virtual Conference. Dr.Jong-Yoon Chun, CEO of Seegene...
Seegene Airlifts 1.7 million COVID-19 Tests to Israel Battling the Omicron Variant by a charter plane
* On December 29, Seegene to deliver Allplex™ SARS-CoV-2 Master Assay that can preemptively detect the Omicron variant at the primary screening stage * Earlier this month, the company has hired a private plane to deliver 2.8 million COVID-19 diagnostic tests to European countries includingItal...
Seegene Rapidly Introduces New PCR Test that Identifies the Omicron Variant, its Stealth Version, and all VOCs in a single tube
SEOUL, South Korea, Dec. 9, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today unveiled another series of diagnostic test that detects the ever-changing COVID-19 variant landscape. The Novaplex™ SARS-CoV-2 Variants VII assay addresses Omicron...
Seegene's High Multiplex PCR Assay Capable of Detecting New Omicron Variant
SEOUL, South Korea, Nov. 30, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today confirmed that its Allplex™ SARS-CoV-2 Master Assay is capable of detecting the Omicron's unique pattern of mutations. The well-established PCR-based test recogni...
Seegene Announces Q3 2021 Earnings, Continuing COVID-Era Momentum
* Q3 Revenue held steady at KRW 305.3 billion * Operating profit dipped slight due to powerful investment in R&D * Scheduled to introduce new diagnostic tests capable of screening 22 targets, including3 genes of COVID-19 and 19 respiratory viruses in a single tube SEOUL, South Korea, Nov. 2...
Seegene Opens New Subsidiary in Bogotá, Colombia, to Advance Regional COVID-19 Testing
SEOUL, South Korea, Nov. 15, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a leading biotechnology firm specializing in molecular diagnostics (MDx), has announced the opening of an eighth global subsidiary, strategically located in Bogotá,Colombia. The new entity, known as 'Seegene Colombia S.A....
Launch of Seegene's STARlet-AIOS: All-in-One System Fulfills Critical Need for Fully Automated, High-Throughput Real-Time PCR Testing
* A true walk away 'sample to answer' molecular diagnostic system designed for high throughput testing, offering a time-efficient and seamless workflow for clinical laboratories * Utilizes Seegene's patented, cutting-edge high multiplex real-time PCR technologies to provide 'Real' Ct values...
Seegene Unveils Fully Automated Molecular Testing System at the 2021 AACC
* Seegene unveils its first fully automated MDx system, STARlet-AIOS: All-in-One System at the 2021 AACC held in theAtlanta, GA, United States * AIOS is the MDx system that integrates Seegene's liquid handler and real-time PCR instruments. * Seegene MDx system will efficiently access a wide ...
Seegene Receives CE-IVD Mark for Use of Combo Swab, a Self-Collection Device with Four COVID-19 Diagnostic Tests
SEOUL, South Korea, Sept. 1, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced on August 20 that it has obtained CE marking for the use of Combo Swab, a self-collection device with four diagnostic assays. Combo Swab is a user-friendly...
Seegene Q2 2021 Earnings Show 11 Percent Revenue Growth, YoY
- Revenue of KRW 303.7 billion ($269.1 million) is record for second quarter, up 11 percent year-over-year - 1H'21 Revenue at KRW 655.5 billion ($580.8 million), 58 percent achievement based on total sales in FY2020 - Favorable market conditions expected in second half amid an increasing dem...
Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Variants Including the Delta and Delta Plus
* Seegene launches new multiplex PCR test capable of screening six SARS-CoV-2 variants including the Delta and Delta Plus variants attributable for a recent surge in global COVID-19 cases. * The new CE-IVD marked variants detection kit to differentiate 10 major COVID-19 variants including the...
Seegene announces partnership with Bio-Rad to develop diagnostic testing products for the U.S. Market
* Seegene announces partnership with Bio-Rad for the development and commercialization of infectious disease molecular diagnostic products * Diagnostic tests designed for the pandemic and the post-pandemic era with high multiplex technology * A significant step forward for Seegene in expandi...
